anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with nortriptyline hydrochloride capsules and should counsel them in their appropriate use. A patient Medication Guide about “Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions” is available for nortriptyline hydrochloride capsules. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking nortriptyline hydrochloride capsules.

###  Clinical Worsening and Suicide Risk

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.

The use of nortriptyline hydrochloride in schizophrenic patients may result in an exacerbation of the psychosis or may activate latent schizophrenic symptoms. If the drug is given to overactive or agitated patients, increased anxiety and agitation may occur. In manic-depressive patients, nortriptyline hydrochloride may cause symptoms of the manic phase to emerge.

Troublesome patient hostility may be aroused by the use of nortriptyline hydrochloride. Epileptiform seizures may accompany its administration, as is true of other drugs of its class.

When it is essential, the drug may be administered with electroconvulsive therapy, although the hazards may be increased. Discontinue the drug for several days, if possible, prior to elective surgery.

The possibility of a suicidal attempt by a depressed patient remains after the initiation of treatment; in this regard, it is important that the least possible quantity of drug be dispensed at any given time.

Both elevation and lowering of blood sugar levels have been reported.
We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
Give cyclosporine 3-5mg/kg/day, adjust the dose based on the blood count, and administer it for at least 6 months to evaluate the efficacy. If effective, the patient will continue to receive cyclosporine treatment for at least 1.5 years, followed by a gradual reduction in dosage.
Autoimmune chronic pancreatitis (AIP) can be defined as a chronic inflammation of the pancreas due to an autoimmune mechanism; autoimmunity is responsible for producing the pancreatic lesion. AIP is a distinctive type of chronic pancreatitis that shows reversible improvement of pancreatic morphology and function with oral steroid therapy, in comparison to other types of chronic pancreatitis which hardly respond to various treatments. AIP is increasingly being recognized to be a worldwide entity. The sudden increment in cases reported probably reflects the growing awareness of the entity, rather than a rise in the true incidence. In previous Japanese report, HLA DRB1\*0405-DQB\*0401 haplotype may be associated with autoimmune pancreatitis in the Japanese population. However, to date there was no subsequent data for supporting these results. In addition, this Japanese study had a limitation in methodology by using a low-resolution typing for HLA. Although this entity is well responsive to steroid therapy, relapse of AIP during steroid treatment is not uncommon. Unfortunately, there has been no laboratory or genetic predictor for responsiveness to steroid therapy in patients with AIP. To further clarify and confirm high-risk and protective genotypes for autoimmune diseases, therefore, high-resolution typing for HLA should be needed. Thus, to determine whether certain alleles or haplotypes of major histocompatibility complex gene are associated with AIP in Korean population, we undertook this study with high-resolution typing for HLA (sequence-based typing).
The MORE study was designed guided by the Individual and Family Self-Management Theory to facilitate adaptation to stoma care within three key patient and caregiver unmet need domains: 1) enhancement of knowledge and beliefs (e.g., outcome expectations), 2) enhancement of ostomy-care competencies (e.g., learning skills and building confidence), and 3) enhancement of self-regulation (e.g., stress management). Content for these domains is organized in a web-based app (STOMA Care) accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modeling competencies. Program software was developed in collaboration with the Information Technology Department at Mount Sinai. A usability testing with 11 patients, caregivers, and nurses showed high acceptability and usability of MORE and led to refinements of the program software. In this proposed pilot study, the research team plan to examine the acceptability and feasibility of the refined MORE in bladder and colorectal cancer patients with new ostomies and their family caregivers. Results from this pilot study will inform a large randomized clinical trial (RCT) of MORE with ostomy patients and their caregivers. Here researchers aim to: Aim 1: Examine the acceptability and feasibility of the refined MORE: The research team will conduct a pilot, randomized, feasibility study with 45 bladder and colorectal cancer patients scheduled for ostomies at Mount Sinai Health System and their family caregivers. The primary outcomes of interest will be measures of feasibility and acceptability of MORE. Feasibility will be evaluated based on the ability to recruit and randomize participants (patient/caregiver dyads) to the two treatment arms (MORE vs. usual care), retain participants for the entire duration of the study period, apply appropriate methods for assessment and implement the program in a diverse, urban ostomy patient population and their family caregivers. Pre- and post-surgical secondary outcomes measured by standardized scales (1 week before surgery; day of discharge, and 4 weeks post-discharge) for the following variables will be used to estimate effect size for powering a larger future RCT: stoma-related knowledge and beliefs, patient stoma-care skills and self-efficacy beliefs, and self-regulation and adaptation (e.g., distress and quality of life). The research team hypothesize that MORE will be acceptable and feasible, will improve patient and caregiver knowledge, stoma-care skills, and quality of life, and will reduce their emotional distress.
PURPOSE:To obtain a composition for cleansing, good in extensibility and having good permeability without thickening even if water is mixed therein by using a hydrophilic nonionic surfactant, an amphoteric surfactant, a water-soluble compound having hydroxyl group, a liquid oil and water together. CONSTITUTION:The composition for cleansing is obtained by using a hydrophilic nonionic surfactant (e.g. a polyoxyethylene alkyl ether), an amphoteric surfactant (e.g. lauryldimethylamine oxide), a water-soluble compound having hydroxyl group (e.g. glycerol or ethanol), a liquid oil (e.g. liquid paraffin or olive oil) and water together. This composition is in a readily handleable gelatinous or liquid form and excellent in feeling of use such as extensibility and slipperiness in application to the skin and good in permeability to fine parts of the skin. This composition is capable of performing the massaging while maintaining smooth touch during the application without thickening even by mixing of water. The composition is converted into ultra-fine oil-in-water type emulsified particles by further addition of water and can readily be removed together with fouling of makeup., etc.
The capsule will contain approximately 15\*10\^9 CFU of Bif195 per day. Excipients: Microcrystalline Cellulose 6 mg per capsule, Magnesium Stearate 1.5 mg per capsule, Maltodextrin 277.8 mg per capsule, and Sodium Ascorbate 14.7 mg per capsule.
Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
The present invention relates to a novel monoclonal antibody and a hybridoma cell line producing said antibody. In addition, subject of the invention is a monoclonal antibody producing hybridoma cell line having the designation 272-17E6 and deposited under accession number DSM ACC2160, as well as a monoclonal antibody having the properties given above and which is obtainable by said hybridoma cell line. Furthermore, the invention relates to DNA sequences and amino acid sequences. The DNA sequences are coding for the antibody or parts of it. The sequences are given in FIG. 17a and 17b and in the attached Sequence Protocol. The subject of the invention is, finally, a pharmaceutical composition comprising an antibody as defined above.
A whitening system for a person's teeth includes a gel having a whitening agent, such as peroxide, contained therein. The gel is supported and carried in a channel formed in the central area of a strip of core material that also functions as a gum protective liner. The core and gum protective liner is preferably made of a biodegradable material or of a similar material that can be washed or brushed away. A release liner may be applied to the top of the combined gel and core and is removed to expose the gel when the system is to be used. Applied to the lower side of the core is a releasable backing layer that supports the gel and core and functions as an applicator for the system. The backing layer maintains the integrity of the core and allows the same to be molded to the surfaces of the teeth without having to directly handle the core with one's hands. To use the system, the release liner is removed and the core is fitted to the teeth with the gel in contact with the teeth and the gum protective liner covering the gum. Once the core has been fitted to the teeth, the backing layer is removed leaving the core in place with the gel and whitening agent remaining on the teeth. After a desired period of time, the core with the whitening gel is washed off, brushed off, pulled off, or is allowed to simply dissolve.
Objective: To systematically evaluate the effect of overtime work on neck musculoskeletal disorders of occupational population in China. Methods: In August 2023, the literatures on the relationship between overtime work and neck musculoskeletal disorders were searched in China National Knowledge Infrasture (CNKI), WanFang Database, Chinese Science & Technology Journal Database (VIP), China Biomedical Literature Service System (SinoMed) and PubMed. The search scope was Chinese and English literatures published before June 30, 2023. The Quality of literature studies was evaluated using the Agency for Healthcare Research and Quality (AHRQ) cross-sectional study quality evaluation criteria. The Stata 15.0 software was used to calculate combined OR values, and subgroup analysis and meta regression were used to explore the sources of heterogeneity. Results: A total of 32 literatures were included, all of which were in Chinese, with a total sample size of 36003 people, and the literature quality scores were 5-7 points. Heterogeneity test showed that there was no heterogeneity between the literatures (I(2)=20.3%, P=0.156), so fixed effect model was selected to calculate the combined OR value. The combined OR value of overtime work on neck musculoskeletal disorders was 1.51 (95%CI: 1.42-1.60, P<0.001). Subgroup analysis showed that the combined OR of occupational population <35 years old group was higher than that in the ≥35 years old group (P<0.05). But there were no significant differences in the combined OR values in the subgroups classified by average years of service, male proportion, type of OR values, sample size and industry classification (P>0.05) . Conclusion: Overtime work is a risk factor for neck musculoskeletal disorders in Chinese occupational population. Working hours should be rationally arranged to reduce the prevalence of neck musculoskeletal disorders.
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primate uPAR, e.g., a cynomolgus uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins and conjugates of the present disclosure to treat a condition associated with uPAR expression and/or activity are also provided. In some embodiments, the condition associated with uPAR expression and/or activity is cancer. Non-limiting examples of such cancers include those characterized by cancer cells that express uPAR on the surface thereof, cancers characterized by stromal cells in the tumor microenvironment that express uPAR on the surface thereof, and/or the like.
Olanzapine, a widely prescribed atypical antipsychotic, poses a great risk to the patient's health by fabricating a plethora of severe metabolic and cardiovascular adverse effects eventually reducing life expectancy and patient compliance. Its heterogenous receptor binding profile has made it difficult to point out a specific cause or treatment for the related side effects. Growing body of evidence suggest that transient receptor potential (TRP) channel subfamily Ankyrin 1 (TRPA1) has pivotal role in pathogenesis of type 2 diabetes and obesity. With this background, we aimed to investigate the role of pharmacological manipulations of TRPA1 channels in antipsychotic (olanzapine)-induced metabolic alterations in female mice using allyl isothiocyanate (AITC) and HC-030031 (TRPA1 agonist and antagonist, respectively). It was found that after 6 weeks of treatment, AITC prevented olanzapine-induced alterations in body weight and adiposity; serum, and liver inflammatory markers; glucose and lipid metabolism; and hypothalamic appetite regulation, nutrient sensing, inflammatory and TRPA1 channel signaling regulating genes. Furthermore, several of these effects were absent in the presence of HC-030031 (TRPA1 antagonist) indicating protective role of TRPA1 agonism in attenuating olanzapine-induced metabolic alterations. Supplementary in-depth studies are required to study TRPA1 channel effect on other aspects of olanzapine-induced metabolic alterations.
The invention relates to a blood circulation invigorating and pain relieving Chinese medicinal composition and a preparation process and an application thereof. The Chinese medicinal composition is characterized by consisting of the following bulk pharmaceuticals in parts by weight: 8-12 parts of himalayan teasel root, 8-12 parts of Chinese taxillus twig, 8-12 parts of cortex eucommiae, calcined pyritum, 5-7 parts of pseudo-ginseng root, 8-12 parts of Chinese yam, 8-12 parts of Chinese angelica, 4-6 parts of dragon bone, 5-7 parts of liquoric root, 8-12 parts of malaytea scurfpea fruit, 8-12 parts of corydalis tuber, 8-12 parts of fortune's drynaria rhizome, 18-22 parts of heterophylly falsestarwort root, 8-12 parts of prepared frankincense, 3-5 parts of borneol and 4-12 parts of ground beetle. The method comprises the following steps of: smashing calcined pyritum, pseudo-ginseng root, Chinese yam and ground beetle into fine powder; grinding borneol according to the specified parts by weight; extracting Chinese angelica in a supercritical way and including; mixing the other medicinal materials with extraction decoction dregs and performing alcohol extraction to obtain alcohol extract fine powder; and uniformly mixing the obtained substances. After the medicaments are used together, the effects of nourishing qi and blood, nourishing liver and kidney and strengthening the bone are achieved. The Chinese medicinal composition is used for treating traumatic injury, and is particularly used for treating middle and later-stage bone fracture. The total effective rate is 96.4 percent.
A non-therapeutic intervention study is described. The Aged Garlic Extract (AGE) supplement (and placebo) intervention occurs over a total of 90 days between mid-January to March. The CDC indicates that this is the cold and flu season (http://www.cdc.gov/flu/weekly/fluactivity.htm ). Blood is taken at baseline and at 45 days, 2 hours after they have taken their capsule. Capsule consumption will continue for a total of 90 days in order to continue monitoring cold and flu symptoms. Subjects will be given a diary to keep a record of their cold and flu symptoms. Peripheral blood mononuclear cells are isolated from the blood draw and used fresh, cultured in autologous serum for 24 hours or cultured in autologous serum for 10 days. Freshly isolated cells will be used for glutathione analysis, for protection against induced DNA strand breaks, and for γδ T cell and NK cell numbers. The supernatant of 24 hour cultures will be used for cytokine determination, specifically, interferon-g, tumor necrosis factor-a and IL-12. Cells cultured for 10 days will be used to determine the rate of proliferation. If cells have been primed by AGE, we expect the AGE cells to proliferate to a greater extent and have greater cytokine secretion compared to placebo.

If AGE enhances the function of one or both of these cell types (NK or γδ T cell), then it is possible that there will be fewer cold and flu symptoms in the group consuming the supplement.
The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
AIMS: In this study, the anticonvulsant action of closed-loop, low-frequency deep brain stimulation (DBS) was investigated. In addition, the changes in brain rhythms and functional connectivity of the hippocampus and prefrontal cortex were evaluated.
METHODS: Epilepsy was induced by pilocarpine in male Wistar rats. After the chronic phase, a tripolar electrode was implanted in the right ventral hippocampus and a monopolar electrode in medial prefrontal cortex (mPFC). Subjects' spontaneous seizure behaviors were observed in continuous video recording, while the local field potentials (LFPs) were recorded simultaneously. In addition, spatial memory was evaluated by the Barnes maze test.
RESULTS: Applying hippocampal DBS, immediately after seizure detection in epileptic animals, reduced their seizure severity and duration, and improved their performance in Barnes maze test. DBS reduced the increment in power of delta, theta, and gamma waves in pre-ictal, ictal, and post-ictal periods. Meanwhile, DBS increased the post-ictal-to-pre-ictal ratio of theta band. DBS decreased delta and increased theta coherences, and also increased the post-ictal-to-pre-ictal ratio of coherence. In addition, DBS increased the hippocampal-mPFC coupling in pre-ictal period and decreased the coupling in the ictal and post-ictal periods.
CONCLUSION: Applying closed-loop, low-frequency DBS at seizure onset reduced seizure severity and improved memory. In addition, the changes in power, coherence, and coupling of the LFP oscillations in the hippocampus and mPFC demonstrate low-frequency DBS efficacy as an antiepileptic treatment, returning LFPs to a seemingly non-seizure state in subjects that received DBS.
5.1 Risk of Cardiac Complications in Elderly and in Patients with Cardiovascular Disease

Excessive bolus dosing of Levothyroxine Sodium for Injection (greater than 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition. Adverse events that can potentially be related to the administration of large doses of Levothyroxine Sodium for Injection include arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death. Cautious use, including doses in the lower end of the recommended range, may be warranted in these populations. Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised.

5.2 Need for Concomitant Glucocorticoids and Monitoring for Other Diseases in Patients with Endocrine Disorders

Occasionally, chronic autoimmune thyroiditis, which can lead to myxedema coma, may occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious anemia, and insulin–dependent diabetes mellitus. Patients should be treated with replacement glucocorticoids prior to initiation of treatment with Levothyroxine Sodium for Injection, until adrenal function has been adequately assessed. Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. With initiation of Levothyroxine Sodium for Injection, patients with myxedema coma should also be monitored for previously undiagnosed diabetes insipidus.

5.3 Not Indicated for Treatment of Obesity

Thyroid hormones, including Levothyroxine Sodium for Injection, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [ See Adverse Reactions (6) and Overdosage (10)].